182 related articles for article (PubMed ID: 18593683)
1. Formulary decisions for pre-1938 medications.
Culley CM; Carroll BA; Skledar SJ
Am J Health Syst Pharm; 2008 Jul; 65(14):1363-7. PubMed ID: 18593683
[TBL] [Abstract][Full Text] [Related]
2. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
Spooner JJ; Gandhi PK; Connelly SB
J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
[TBL] [Abstract][Full Text] [Related]
3. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
4. The US Food and drug administration: drug information resource for formulary recommendations.
Marchand HC; Ros BJ; Fine AM; Kremzner ME
J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
[TBL] [Abstract][Full Text] [Related]
5. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
Ostroff C; Lee CE; McMeekin J
Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
[TBL] [Abstract][Full Text] [Related]
6. Application of pharmacoeconomics to formulary management in a health system setting.
Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
[TBL] [Abstract][Full Text] [Related]
7. Physician satisfaction with formulary policies: is it access to formulary or nonformulary drugs that matters most?
Glassman PA; Good CB; Kelley ME; Bradley M; Valentino M
Am J Manag Care; 2004 Mar; 10(3):209-16. PubMed ID: 15032258
[TBL] [Abstract][Full Text] [Related]
8. Weighing the evidence: trends in managed care formulary decision making.
de Lissovoy G
J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
[TBL] [Abstract][Full Text] [Related]
9. Association between FDA black box warnings and Medicare formulary coverage changes.
Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
[TBL] [Abstract][Full Text] [Related]
10. Formularies in integrated health systems: Fallon Healthcare System.
Cano SB
Am J Health Syst Pharm; 1996 Feb; 53(3):270-3. PubMed ID: 8808021
[TBL] [Abstract][Full Text] [Related]
11. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
Fry RN; Avey SG; Sullivan SD
Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
[TBL] [Abstract][Full Text] [Related]
12. The formulary decision-making process in a US academic medical centre.
Nash DB; Catalano ML; Wordell CJ
Pharmacoeconomics; 1993 Jan; 3(1):22-35. PubMed ID: 10146985
[TBL] [Abstract][Full Text] [Related]
13. Unapproved drugs in the United States and the Food and Drug Administration.
Nasr A; Lauterio TJ; Davis MW
Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
[TBL] [Abstract][Full Text] [Related]
14. How drug life-cycle management patent strategies may impact formulary management.
Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
[TBL] [Abstract][Full Text] [Related]
15. Deciding which drugs get onto the formulary: a value-based approach.
Seigfried RJ; Corbo T; Saltzberg MT; Reitz J; Bennett DA
Value Health; 2013; 16(5):901-6. PubMed ID: 23947985
[TBL] [Abstract][Full Text] [Related]
16. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
Lexchin J
Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
[TBL] [Abstract][Full Text] [Related]
17. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
18. Review of purchases of unapproved medications by the Veterans Health Administration.
Carico RL; Emmendorfer TR; Aspinall SL; Mizah MT; Good CB
Am J Health Syst Pharm; 2019 Nov; 76(23):1934-1943. PubMed ID: 31628792
[TBL] [Abstract][Full Text] [Related]
19. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
[TBL] [Abstract][Full Text] [Related]
20. The formulary decision-making process in a health maintenance organisation setting.
Shepherd MD; Salzman RD
Pharmacoeconomics; 1994 Jan; 5(1):29-38. PubMed ID: 10146864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
